Significant attention has focused on the role of low-density lipoprotein (LDL) in the pathogenesis of atherosclerosis. However, recent advances have identified triglyceride-rich lipoproteins [e.g., very LDL (VLDL)] as independent risk predictors for this disease. We have previously demonstrated peroxisome proliferator-activated receptor (PPAR)␦, but not PPAR␥, is the major nuclear VLDL sensor in the macrophage, which is a crucial component of the atherosclerotic lesion. Here, we show that, in addition to -oxidation and energy dissipation, activation of PPAR␦ by VLDL particles induces key genes involved in carnitine biosynthesis and lipid mobilization mediated by a recently identified TG lipase, transport secretion protein 2 (also named desnutrin, iPLA2, and adipose triglyceride lipase), resulting in increased fatty acid catabolism. Unexpectedly, deletion of PPAR␦ results in derepression of target gene expression, a phenotype similar to that of ligand activation, suggesting that unliganded PPAR␦ suppresses fatty acid utilization through active repression, which is reversed upon ligand binding. This unique transcriptional mechanism assures a tight control of the homeostasis of VLDL-derived fatty acid and provides a therapeutic target for other lipid-related disorders, including dyslipidemia and diabetes, in addition to coronary artery disease. At the cellular level, they are indispensable in maintaining cell membrane integrity and serve as signaling molecules regulating metabolic balance. An excessive lipid intake, through the socalled western-style diet, disturbs this balance and is the main cause of obesity-related diseases (or syndrome X) in developed countries (2). The development of drugs that could control circulating lipid levels, such as lowering VLDL TGs and LDL cholesterol and raising high-density lipoprotein cholesterol, has been a major focus for the pharmaceutical industry. These efforts have shown promise in treating diseases, including hyperlipidemia and cardiovascular dysfunctions.Peroxisome proliferator-activated receptors (PPARs) belong to the nuclear receptor superfamily and are bound and activated by fatty acids (3). There are three subtypes in this subfamily, PPAR␣, PPAR͞␦, and PPAR␥, each exhibiting a distinct tissue distribution and regulating different aspects of lipid homeostasis (4, 5). PPAR␣ plays a major role in fatty acid oxidation in liver during fasting (6, 7), whereas PPAR␥ is important for lipid storage, adipocyte functions, and insulin sensitivity (8-12). These important biological activities of PPAR␣ and PPAR␥ have later been proven responsible for the TG-lowering effect of fibrates and the insulin-sensitizing activity of thiazolidinediones, respectively (13-16). The function of ubiquitously expressed PPAR␦ was less defined until the making of genetically modified animals. Transgenic mice expressing an active form of PPAR␦ in adipocytes are resistant to diet-induced obesity due to an increased fatty acid catabolic rate (17). Paradoxically, PPAR␦Ϫ͞Ϫ mice are also lean (18, 19), ...